Thanin Srisethi - DOD Biotech Director CEO
| DOD Stock | 2.10 0.12 5.41% |
Insider
Thanin Srisethi is Director CEO of DOD Biotech Public
| Age | 44 |
| Phone | 66 3 444 6333 |
| Web | https://www.dodbiotech.com |
DOD Biotech Management Efficiency
The company has return on total asset (ROA) of 0.0281 % which means that it generated a profit of $0.0281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.04 %, meaning that it generated $0.04 on every $100 dollars invested by stockholders. DOD Biotech's management efficiency ratios could be used to measure how well DOD Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Suporn Samakkabutr | Carabao Group Public | 63 | |
| Yuenyong Opakul | Carabao Group Public | 68 | |
| Deepak Panjwani | Mega Lifesciences Public | 49 | |
| Kamoldist Smuthkochorn | Carabao Group Public | 63 | |
| Sujintana Boonworapat | Mega Lifesciences Public | 51 | |
| Siripong Wongskhunti | Carabao Group Public | N/A | |
| Nonglak Laksanapokin | Jay Mart Public | 63 | |
| Manee Soonthornvatin | Jay Mart Public | 67 | |
| Achiraya Sitakaradech | Carabao Group Public | 43 | |
| Kanokporn Sukprasitpredee | KCE Electronics Public | N/A | |
| Supamas Khaikaew | Jay Mart Public | N/A | |
| Duangnapa Tongsiri | Mega Lifesciences Public | 63 | |
| Waranchai Jensiriwanich | Carabao Group Public | 51 | |
| Adisak Sukumvitaya | Jay Mart Public | 67 | |
| Yuvadee PongAcha | Jay Mart Public | 67 | |
| Urawee Ngowroongrueng | Carabao Group Public | N/A | |
| Kanit Patsaman | Carabao Group Public | 52 | |
| Panya Chutisiriwong | Jay Mart Public | N/A | |
| Chayanee Chaidetkhajorn | KCE Electronics Public | N/A | |
| Nutchamai Thanombooncharoen | Carabao Group Public | 61 | |
| Kittipat Chonlawut | Jay Mart Public | N/A | |
Management Performance
| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 |
DOD Biotech Public Leadership Team
Elected by the shareholders, the DOD Biotech's board of directors comprises two types of representatives: DOD Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DOD. The board's role is to monitor DOD Biotech's management team and ensure that shareholders' interests are well served. DOD Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DOD Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dusit Chongsutthanamanee, Independent Sec | ||
| Thanin Srisethi, Director CEO | ||
| Suwarin Konthong, Chief CFO | ||
| Nattawat Phetthai, Accounting Accountant | ||
| Torlarp Chaiyachow, Acting Chairman | ||
| Aekphusit Boonsiriyotthakul, COO Director |
DOD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DOD Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 2.04 B | |||
| Shares Outstanding | 410 M | |||
| Shares Owned By Insiders | 48.01 % | |||
| Shares Owned By Institutions | 2.38 % | |||
| Price To Book | 1.47 X | |||
| Price To Sales | 2.55 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.